National Hemophilia Foundation

Foundation says it's not deterred by Avigen gene-transfer therapy announcement

Published in Managed Care Business Week, June 29th, 2004

Despite the recent announcement by biotechnology company Avigen that it will discontinue its development of a gene-transfer therapy for hemophilia, the National Hemophilia Foundation (NHF) remains optimistic about the potential for gene transfer and other investigational therapies for hemophilia and will continue to support such research.

"We are confident that breakthroughs in recent years, and those to come, will lead us to a cure for bleeding disorders," said NHF President Richard Metz, MD. "This is a time to redouble our efforts to support promising research so that breakthroughs for hemophilia and all genetic diseases will happen sooner, not later," Metz...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Managed Care Business Week

Source: Managed Care Business Week (2004-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry